8-K: HeartSciences Boosts ATM Offering to $25M

HeartSciences Inc. amended its at-the-market equity distribution agreement, increasing the potential capital raise to $25 million and adjusting sales agent commissions.

Summary

• HeartSciences Inc. (HSCS) entered into Amendment No. 3 to its Equity Distribution Agreement (EDA) with Maxim Group LLC on August 3, 2025.
• The amendment increases the aggregate amount of common stock the company may offer and sell through an at-the-market (ATM) offering from $15,000,000 to $25,000,000.
• The sales agent, Maxim Group LLC, will receive a commission of 4.0% of the gross sales price for shares sold up to the existing ATM limit of $646,344.22, and 3.0% for any sales exceeding this amount.
• As of July 31, 2025, the aggregate market value of common stock held by non-affiliates was $14,737,609, based on 2,276,253 shares and a closing price of $5.73 on July 10, 2025.
• The company will reimburse Maxim Group LLC for legal fees totaling $5,000.00 ($2,500 for the amendment and $2,500 for the 10-K bringdown).

Sentiment

Score: 5

Explanation: The increased capital raising capacity is positive for liquidity and flexibility, but the potential for significant shareholder dilution and the current regulatory limitations on the amount that can be sold temper the overall sentiment to neutral. The adjusted commission structure is slightly favorable for larger sales volumes.

Positives

• Increased financial flexibility and access to capital, with the potential to raise up to an additional $10 million.
• A reduced commission rate of 3.0% for sales exceeding the initial $646,344.22 threshold, potentially lowering capital raising costs for larger amounts.

Negatives

• Potential for significant shareholder dilution as new shares are sold into the market.
• The company's non-affiliate float of $14,737,609 limits the amount that can be sold under Form S-3 General Instruction I.B.6 to approximately $4.9 million within a 12-month period, potentially restricting the full $25 million raise.
• Legal fees of $5,000.00 associated with the amendment and related filings.

Risks

• Dilution Risk: The sale of additional common stock through the ATM offering will dilute the ownership interest of existing shareholders.
• Market Price Volatility: The actual amount of capital raised will depend on the market price of the common stock and investor demand, which can be volatile.
• Regulatory Limitations: Sales are subject to Form S-3 eligibility and transaction requirements, specifically General Instruction I.B.6, which limits sales to one-third of the non-affiliate float if it's below $75 million.
• Execution Risk: The ability to execute the ATM offering successfully depends on the sales agent's performance and market conditions.

Future Outlook

The company has increased its capacity to raise capital through equity sales, providing flexibility for future funding needs. The ability to sell shares is subject to market conditions and regulatory limitations, particularly the one-third rule for companies with a public float under $75 million.

Management Comments

• Andrew Simpson, President, Chief Executive Officer, and Chairman of the Board of Directors, signed the Form 8-K on behalf of HeartSciences Inc.

Industry Context

At-the-market (ATM) offerings are a common and flexible capital-raising tool for publicly traded companies, particularly those with smaller market capitalizations or those seeking to manage dilution over time. This amendment indicates HeartSciences' intent to maintain or increase its financial liquidity and fund ongoing operations or strategic initiatives, a typical move in industries requiring continuous investment.

Comparison to Industry Standards

• This filing does not provide specific operational or financial results to compare against industry benchmarks or competitors. The ATM offering itself is a standard capital-raising mechanism.
• The commission rates (4.0% dropping to 3.0%) are within typical ranges for ATM facilities, which can vary based on the size of the offering, the company's market capitalization, and the sales agent's terms. For example, smaller cap companies might see rates from 2.5% to 5%.

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholdings as new shares are issued.
• Company: Enhanced financial flexibility and access to capital for operations or strategic initiatives.
• Sales Agent (Maxim Group LLC): Will earn commissions on shares sold through the ATM offering.

Next Steps

• Potential future sales of common stock under the amended at-the-market offering, subject to market conditions and regulatory limits.
• Ongoing compliance with Form S-3 eligibility and transaction requirements.

Key Dates

Recommendation

The filing primarily concerns an increase in the company's capacity to raise capital through an at-the-market offering. While this provides financial flexibility, it also introduces the risk of dilution for existing shareholders. Without further information on the company's specific use of proceeds, current financial performance, or strategic plans, it is difficult to assess the net impact on shareholder value. Investors should hold and monitor future disclosures regarding the deployment of these funds and the actual pace of share issuance.

Keywords

HeartSciences, HSCS, ATM offering, equity distribution agreement, capital raise, common stock, Maxim Group, SEC filing, Form 8-K, dilution, S-3 filing, at-the-market